<DOC>
	<DOCNO>NCT00083668</DOCNO>
	<brief_summary>The primary objective double-blind phase study evaluate efficacy safety 3 fix dosage paliperidone ER ( 3 , 9 , 15 mg/day ) compare placebo adult patient schizophrenia</brief_summary>
	<brief_title>Trial Evaluating Three Fixed Doses Paliperidone Extended-Release ( ER ) Tablets Olanzapine Treatment Patients With Schizophrenia</brief_title>
	<detailed_description>Paliperidone develop new therapeutic agent treatment schizophrenia . The extended-release ( ER ) formulation paliperidone develop deliver paliperidone relatively constant rate 24-hour period improve tolerability profile decrease potential orthostatic hypotension . This study design evaluate efficacy safety tolerability 3 dosage paliperidone ER compare placebo adult patient schizophrenia . This multicenter , double-blind , randomize , placebo- active-controlled , parallel-group , dose-response study . Patients randomize 1 5 treatment group receive oral dosage paliperidone ER 3 , 9 , 15 mg , olanzapine 10 mg , placebo daily 6-week period . The study include screening period 5 day , follow 6-week double-blind treatment phase . Following double-blind treatment phase , eligible patient ( complete 6-week double-blind phase discontinue due lack efficacy minimum 21 day ) may enter 52-week open-label extension paliperidone ER monotherapy . While patient hospitalize , efficacy assess twice first week end second week , patient discharge hospital , return efficacy safety assessment perform weekly basis end 6-week double-blind phase . Efficacy evaluate throughout 6-week double-blind phase completion Positive Negative Syndrome Scale ( PANSS ) , Clinical Global Impression Scale - Severity ( CGI-S ) , Personal Social Performance Scale ( PSP ) , Schizophrenia Quality Life Scale , Revision 4 ( SQLS-R4 ) . The primary efficacy response measure change baseline score end double-blind phase PANSS total score . Safety monitor throughout study include assessment incidence adverse event ; measurement extrapyramidal symptom use 3 rating scale ( Abnormal Involuntary Movement Scale [ AIMS ] , Barnes Akathisia Rating Scale [ BARS ] , Simpson-Angus Rating Scale [ SAS ] ) ; measurement vital sign ( lay stand blood pressure , pulse , temperature ) ; electrocardiogram ; clinical laboratory test . Double-blind phase : 3 , 9 , 15 mg paliperidone ER , 10 mg olanzapine placebo take orally day 6 week . Open-label phase : start paliperidone ER 9 mg orally day ; maintain flexible oral dosage paliperidone ER ( 3 , 6 , 9 , 12 , 15 mg/day ) 52 week .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Doubleblind phase : DSMIV diagnosis schizophrenia least 1 year experience acute episode , total PANSS score screen 70 120 agree voluntary hospitalization minimum 14 day willing able fill selfadministered questionnaire must able compliant selfadministration medication , consistent help/support available . Openlabel phase : complete 6 week doubleblind treatment complete least 21 day treatment discontinue due lack efficacy patient investigator must agree openlabel treatment best interest patient . Doubleblind phase : DSMIV axis I diagnosis schizophrenia DSMIV diagnosis substance dependence within 6 month prior screen evaluation ( nicotine caffeine dependence exclusionary ) history tardive dyskinesia neuroleptic malignant syndrome ( NMS ) history severe preexist gastrointestinal narrowing ( pathologic iatrogenic ) previous history lack response ( 2 adequate trial ) antipsychotic significant risk suicidal violent behavior . Openlabel extension : patient believe investigator significant risk suicidal violent behavior receive injection depot antipsychotic since entry precede doubleblind phase .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2010</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Paliperidone</keyword>
	<keyword>Olanzapine</keyword>
	<keyword>PANSS</keyword>
	<keyword>Extended release</keyword>
	<keyword>Atypical neuroleptic</keyword>
</DOC>